- Satellos Bioscience (MSCL) has obtained a high-resolution (1.85Å) crystal structure of its drug target for Duchenne muscular dystrophy
- The company believes the image could accelerate its lead optimization program
- The company’s drug candidates regulate an enzyme that controls muscle stem cell function, allowing them to properly divide and repair damaged tissue
- Satellos is dedicated to developing therapeutics that stimulate or restore muscle regeneration in severe disorders
- Satellos Bioscience (MSCL) closed unchanged trading at $1.55 per share
Satellos Bioscience (MSCL) has obtained a high-resolution (1.85Å) crystal structure of its drug target for Duchenne muscular dystrophy.
Satellos is developing drugs that restore faulty regeneration and repair in Duchenne patients and other degenerative muscle disorders.
The company’s drug candidates regulate PTP-X, an enzyme that controls muscle stem cell function, allowing stem cells to properly divide and repair damaged tissue in Duchenne patients.
Frank Gleeson, CEO of Satellos, commented,
“These findings represent a huge step forward in our scientific efforts to design highly potent small molecule inhibitors of PTP-X. Until this point, a reliable, high-quality image of our drug target has simply not been available. With this key foundational piece now in place, we have the potential to accelerate our lead optimization program with our already potent compounds and achieve one of our key goals, namely, the timely nomination of a development candidate.”
Dr. Sridhar Narayan, VP of Drug Discovery and Program Leadership at Satellos added,
“We are thrilled to have identified the specific conditions that must be met in order to generate this high-quality, 1.85Å resolution crystal structure of PTP-X and have already begun the process of generating co-crystals with our small molecule drug candidates, meant to pinpoint precisely where they bind the target.
Generation of co-crystal structures will significantly boost our ability to conduct design-make-test cycles critical for lead optimization and achieving the most desirable balance of drug-like properties as quickly as possible.”
Satellos is dedicated to developing therapeutics that stimulate or restore muscle regeneration in severe disorders.
Satellos Bioscience (MSCL) closed unchanged trading at $1.55 per share.
